Editorial Comment
Evolving Concepts in the Management of Congenital Junctional Ectopic Tachycardia Paul C. Gillette, MD Junctional automatic ectopic tachycardias remain one of the most challenging dysrhythmias facing physicians who treat children. In this issue of Circulation, Villain et all report that despite advances in pharmacologic and device therapy, 35% of patients died of congenital junctional ectopic tachycardia.1 These data were collected over a prolonged period of time, and the prognosis today is probably somewhat better. The other form of junctional automatic ectopic tachycardia common to pediatric patients, postsurgical junctional ectopic tachycardia, has been equally devastating.2 These two entities have similarities and differences. They possible that the "French" dose of amiodarone is more effective than the "American" dose, at least in the treatment of this dysrhythmia. In addition, a regimen of dose per square meter of body surface in infants yields a higher dose than does a per-kilogram regimen.
This disease entity calls into question our methods of treating patients with rare diseases. Must we have a double-blind multicenter trial before we can determine how to treat a patient for whom there is no standard therapy? No! It is the physician's duty to treat a sick patient to the best of his or her ability. He or she must use experience with other similar disease processes. The physician should blend the principle of doing no harm with that of protecting the patient from harm. In the treatment of this disease, it is clear that catheter and surgical ablation should be reserved for the very ill patient for whom medical treatment has failed or who is not likely to survive long enough to determine whether medical treatment will work. Ablation treatment of this dysrhythmia is unproven and carries considerable short-and longterm risk, although DC or radiofrequency catheter ablation may prove life-saving in refractory patients. On the other hand, the implantation of a permanent pacemaker carries little risk and should prove effective in some patients based on both pathologic studies and clinical studies. Thus, a combination of initial permanent pacemaker implantation with the French dose of amiodarone is probably the conservative treatment of this dysrhythmia at the present time.
A final caveat is that patients with rare, lifethreatening dysrhythmias are probably best treated in large quaternary referral centers. These centers should be encouraged to treat such patients under prearranged multicenter protocols. Because there is little financial incentive for industry to fund studies of rare diseases, government should do so either directly through the National Institutes of Health or indirectly through social programs. A rare cardiac dysrhythmia that requires expensive medical and drug treatment and familial travel is truly a disabling condition!
